Study register · detail
Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting.
No direction reported
Sample—
Summary
Randomized controlled trial (pilot + RCT) in cancer patients undergoing palliative single-dose radiotherapy to emetogenic regions. The cannabinoid levonantradol (0,5 and 0,75 mg) was compared with the standard antiemetic chlorpromazine. Both substances were well tolerated, but the frequency of vomiting was similar in all three groups, i.e. the cannabinoid showed no advantage over chlorpromazine. Small sample size, old design (1982), negative result.
Authors
Share
Abstract
Levonantradol is a cannabis derivative. Cannabinoid anti-emetics are being assessed in cancer chemotherapy but have been little used in radiotherapy to date. A pilot study and randomised trial compared the anti-emetic effect of a standard drug (Chlorpromazine 26 mg) with Levonantradol at two doses (0.5 and 0.75 mg) in patients receiving palliative single fraction radiotherapy to sites likely to cause nausea and vomiting. Most patients were out-patients. Both drugs were well tolerated. The frequency of vomiting was similar in all three groups in both the pilot study and randomised trial.
The impediment to action advances action.